Compare BEN & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEN | ICLR |
|---|---|---|
| Founded | 1947 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 14.3B |
| IPO Year | N/A | 1998 |
| Metric | BEN | ICLR |
|---|---|---|
| Price | $23.40 | $185.83 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 14 |
| Target Price | $23.05 | ★ $201.23 |
| AVG Volume (30 Days) | ★ 4.3M | 1.0M |
| Earning Date | 11-07-2025 | 10-22-2025 |
| Dividend Yield | ★ 5.47% | N/A |
| EPS Growth | ★ 7.28 | N/A |
| EPS | 0.91 | ★ 7.47 |
| Revenue | ★ $8,770,700,000.00 | $8,102,602,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.60 | $0.76 |
| P/E Ratio | $25.71 | ★ $24.87 |
| Revenue Growth | ★ 3.45 | N/A |
| 52 Week Low | $16.25 | $125.10 |
| 52 Week High | $26.08 | $228.29 |
| Indicator | BEN | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 60.98 | 62.18 |
| Support Level | $22.34 | $174.13 |
| Resistance Level | $23.54 | $191.15 |
| Average True Range (ATR) | 0.46 | 8.46 |
| MACD | 0.19 | 2.87 |
| Stochastic Oscillator | 94.44 | 85.77 |
Franklin Resources provides investment services for individual and institutional investors. At the end of July 2025, Franklin had $1.617 trillion in managed assets, composed primarily of equity (41%), fixed-income (27%), multi-asset/balanced (11%) funds, alternatives (16%) and money market funds (5%). Distribution tends to be weighted between retail investors (56% of AUM) and institutional accounts (41%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the US-based asset managers we cover, with 31% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.